Yi Que Juan Wang Jia Zhu Na Li Junting Huang Suying Lu Feifei Sun Lian Zhang Zijun Zhen Li Zhang Ruiqing Cai Haixia Guo Xiaofei Sun Yizhuo Zhang
10.3389/fimmu.2021.647733
Front Immunol
2021 Jul 6;12:647733.
pd-1 antibody pd-l1 combination monotherapy pediatric cancer
CC BY
https://pubmed.ncbi.nlm.nih.gov/34295326/
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Burkitt Lymphoma / therapy Hodgkin Disease / therapy Immune Checkpoint Inhibitors / therapeutic use Immunotherapy / methods Melanoma / therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Skin Neoplasms / therapy
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Burkitt Lymphoma / therapy Hodgkin Disease / therapy Immune Checkpoint Inhibitors / therapeutic use Immunotherapy / methods Melanoma / therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Skin Neoplasms / therapy Clinical Trial Multicenter Study Observational Study Research Support, Non-U.S. Gov't Adolescent Burkitt Lymphoma / epidemiology Burkitt Lymphoma / immunology Child Child, Preschool China / epidemiology Drug Therapy, Combination / methods Female Follow-Up Studies Hodgkin Disease / epidemiology Hodgkin Disease / immunology Humans Infant Male Melanoma / epidemiology Melanoma / immunology Retrospective Studies Skin Neoplasms / epidemiology Skin Neoplasms / immunology Treatment Outcome Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors PDCD1 protein, human Programmed Cell Death 1 Receptor
PMC8290852
34295326
Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
2021